Chris Boerner

Fierce Pharma

BMS touts commercial execution, reckons with clinical setbacks

Four failed phase 3 trials of BMS' growth products "collectively have relatively limited impact on the long-term growth of the company," the CEO said.

Angus Liu Jul 31, 2025 11:10am

Graphic of a one dollar bill with nuts and bolts scattered across it

BMS more likely to bet on bolt-ons after recent buying spree

Feb 2, 2024 10:59am